Loading...
Docoh

Aptinyx (APTX)

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate-rather than block or over-activate-NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson's disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders.

APTX stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

4 Aug 22
1 Oct 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 85.47M 85.47M 85.47M 85.47M 85.47M 85.47M
Cash burn (monthly) 4.96M 3.67M 5.7M 6.41M 4.92M 5.7M
Cash used (since last report) 15.18M 11.22M 17.44M 19.59M 15.04M 17.42M
Cash remaining 70.29M 74.25M 68.03M 65.88M 70.42M 68.05M
Runway (months of cash) 14.2 20.2 11.9 10.3 14.3 11.9

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
26 May 22 Henry O Gosebruch Stock Option Common Stock Grant Acquire A No No 0.5 40,000 20K 40,000
26 May 22 Hombach Robert J. Stock Option Common Stock Grant Acquire A No No 0.5 40,000 20K 40,000
26 May 22 Enright Patrick G Stock Option Common Stock Grant Acquire A No No 0.5 40,000 20K 40,000
26 May 22 Gilmore Neil O'Neill Stock Option Common Stock Grant Acquire A No No 0.5 40,000 20K 40,000
26 May 22 Joan W. Miller Stock Option Common Stock Grant Acquire A No No 0.5 40,000 20K 40,000
81.0% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 46 67 -31.3%
Opened positions 1 63 -98.4%
Closed positions 22 0 NEW
Increased positions 8 0 NEW
Reduced positions 13 0 NEW
13F shares Current Prev Q Change
Total value 87.95M 152.47M -42.3%
Total shares 54.88M 56.47M -2.8%
Total puts 0 445.1K EXIT
Total calls 46K 521.8K -91.2%
Total put/call ratio 0.9
Largest owners Shares Value Change
Bain Capital Life Sciences Investors 8.89M $4.96M 0.0%
Bain Capital Life Sciences Fund 8.07M $24.12M 0.0%
Artal 6.12M $3.41M 0.0%
Artal International S.C.A. 6.12M $25.69M 0.0%
Adams Street Partners 5.4M $3.01M 0.0%
New Leaf Ventures III 3.29M $8.79M 0.0%
New Leaf Venture Partners, L.L.C. 3.29M $1.84M 0.0%
Frazier Life Sciences VIII 3.19M $10.27M 0.0%
Vanguard 1.96M $1.1M 0.0%
Frazier Life Sciences Management 1.88M $1.05M 0.0%
Largest transactions Shares Bought/sold Change
Point72 Asset Management 410.42K -704.58K -63.2%
AWH Capital 0 -489.86K EXIT
Renaissance Technologies 568.91K +305.99K +116.4%
BLK Blackrock 1.03M -290.32K -22.1%
Susquehanna International 0 -222.27K EXIT
Millennium Management 1.52M +202.65K +15.4%
Two Sigma Investments 227.49K +189.42K +497.6%
Dimensional Fund Advisors 0 -140.71K EXIT
Victory Capital Management 0 -140.36K EXIT
Simplex Trading 200 -105.52K -99.8%

Financial report summary

?
Risks
  • We may fail to continue to meet the listing standards of Nasdaq and, as a result, our common stock may be delisted, which could have a material adverse effect on the liquidity of our common stock.
Management Discussion
  • Research and development expenses were $11.9 million for the three months ended June 30, 2022, compared to $14.8 million for the three months ended June 30, 2021. The net decrease of approximately $2.9 million was primarily due to the following:
  • General and administrative expenses were $5.1 million for each of the three months ended June 30, 2022, and June 30, 2021, respectively.
  • We recorded $0.2 million of other income for the three months ended June 30, 2022, compared to less than $0.1 million of other income for the three months ended June 30, 2021. This was primarily driven by a change in fair value of the derivative liability.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. senior Avg
New words: deficiency, notifying
Removed: registration, stage, suspension